IFRX
Price:
$1.56
Market Cap:
$84.33M
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune dis...[Read more]
Industry
Biotechnology
IPO Date
2017-11-07
Stock Exchange
NASDAQ
Ticker
IFRX
According to InflaRx N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 8.91. This represents a change of -1.63% compared to the average of 9.06 of the last 4 quarters.
The mean historical Current Ratio of InflaRx N.V. over the last ten years is 11.92. The current 8.91 Current Ratio has changed 7.38% with respect to the historical average. Over the past ten years (40 quarters), IFRX's Current Ratio was at its highest in in the June 2018 quarter at 43.98. The Current Ratio was at its lowest in in the March 2016 quarter at 0.
Average
11.92
Median
8.46
Minimum
5.10
Maximum
26.01
Discovering the peaks and valleys of InflaRx N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 111.50%
Maximum Annual Current Ratio = 26.01
Minimum Annual Increase = -58.50%
Minimum Annual Current Ratio = 5.10
Year | Current Ratio | Change |
---|---|---|
2023 | 6.50 | -13.10% |
2022 | 7.48 | 46.60% |
2021 | 5.10 | -40.30% |
2020 | 8.54 | 0.97% |
2019 | 8.46 | -58.50% |
2018 | 20.39 | -21.59% |
2017 | 26.01 | 54.55% |
2016 | 16.83 | 111.50% |
The current Current Ratio of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
6.36
5-year avg
7.22
10-year avg
11.92
InflaRx N.V.’s Current Ratio is greater than Generation Bio Co. (7.42), greater than Kronos Bio, Inc. (8.49), less than Erasca, Inc. (16.79), greater than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (30.24), less than Kezar Life Sciences, Inc. (9.58), less than Fulcrum Therapeutics, Inc. (22.07), greater than Passage Bio, Inc. (7.67), less than Acumen Pharmaceuticals, Inc. (17.37), greater than Galera Therapeutics, Inc. (5.63), less than Inozyme Pharma, Inc. (9.84), less than Eledon Pharmaceuticals, Inc. (14.48), less than Icosavax, Inc. (18.06), less than Ocuphire Pharma, Inc. (10.68), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Protalix BioTherapeutics, Inc. (1.33), greater than EyePoint Pharmaceuticals, Inc. (4.75), greater than SELLAS Life Sciences Group, Inc. (1.02), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67),
Company | Current Ratio | Market cap |
---|---|---|
7.42 | $144.16M | |
8.49 | $57.28M | |
16.79 | $810.79M | |
6.31 | $455.30M | |
30.24 | $3.23B | |
9.58 | $51.73M | |
22.07 | $203.43M | |
7.67 | $37.34M | |
17.37 | $177.24M | |
5.63 | $2.64M | |
9.84 | $277.29M | |
14.48 | $280.20M | |
18.06 | $769.04M | |
10.68 | $31.74M | |
0.41 | $33.39M | |
1.33 | $94.13M | |
4.75 | $775.07M | |
1.02 | $75.27M | |
6.56 | $542.54M | |
41.42 | $301.22M | |
12.13 | $98.77M | |
18.22 | $83.00M | |
6.67 | $689.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is InflaRx N.V.'s Current Ratio?
How is the Current Ratio calculated for InflaRx N.V. (IFRX)?
What is the highest Current Ratio for InflaRx N.V. (IFRX)?
What is the 3-year average Current Ratio for InflaRx N.V. (IFRX)?
What is the 5-year average Current Ratio for InflaRx N.V. (IFRX)?
How does the current Current Ratio for InflaRx N.V. (IFRX) compare to its historical average?